Pfizer sells ViiV stake for $1.875B and expands tafamidis capacity
Pfizer sold its 11.7% ViiV Healthcare stake for $1.875 billion, boosting liquidity. In 2023, it shipped 2.3 million tafamidis capsules and added a second production line at its Freiburg plant in February 2024 to clear back-orders for its amyloidosis therapy.
Related News
VBCG
Vanguard’s BondBuilder ETFs Gather $242M in Two Months with 0.08% Fees
VBCG•
GROW
US Global Investors Sees 15% AUM Gain, 31% Revenue Growth and $2.6M Profit
GROW•
NVDA
Nvidia posts US$81.6B Q1 revenue, forecasts US$91B for Q2
NVDA•
TJX
TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch
TJX•
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
Sources
YFGBG
+1 more